The new core drug and vaccine division, which CEO Emma Walmsley has dubbed "New GSK," has set targets of 5% sales growth and 10% profit growth between now and 2026.
The new core drug and vaccine division, which CEO Emma Walmsley has dubbed "New GSK," has set targets of 5% sales growth and 10% profit growth between now and 2026. The separation is expected to take effect in mid-2022. Investors have reacted positively to the plans thus far, with GSK shares up 3% by mid-afternoon trade in Europe.at the company's Capital Markets Day, having been under pressure of late from U.S. activist investor Elliott Management. The virtual session begins at 2 p.m. London time on Wednesday.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: